Design of Insulin Variants for Improved Treatment of Diabetes - Peptide and Protein Design for Biopharmaceutical Applications - page 278

[82] ˚ . Vølund, U. Ribel, P. L. Dam, J. Markussen, L. Langkjaer, J. Dolben and
D. R. Owens, Application of the euglycaemic clamp technique to bioassay of insulin
analogues, Biologicals: J. Inter. Assoc. Biol. Stand ., 20, 135-142 (1992).
[83] J. Buse, Insulin glargine (HOE901), Diabetes Care , 23, 576-578 (2000).
[84] P. Home, Insulin glargine: The first clinically useful extended-acting insulin in half a
century?, Exp. Opin. Invest. Drugs , 8, 307-314 (1999).
[85] G. B. Bolli and D. R. Owens, Insulin glargine, Lancet , 356, 443-445 (2000).
[86] M. Bahr, T. Kolter, G. Seipke and J. Eckel, Growth promoting and metabolic activity
of the human insulin analogue GlyA21,ArgB31, ArgB32insulin (HOE 901) in muscle
cells, Eur. J. Pharm ., 320, 259-265 (1997).
[87] P. Kurtzhals, L. Schaffer, A. Sørensen, C. Kristensen, I. Jonassen, C. Schmid and
T. Trub, Correlations of receptor binding and metabolic and mitogenic potencies of
insulin analogs designed for clinical use, Diabetes , 49, 999-1005 (2000).
[88] W. D. Kohn, R. Micanovic, S. L. Myers, A. M. Vick, S. D. Kahl, L. Zhang,
B. A. Strifler, S. Li, J. Shang, J. M. Beals, J. P. Mayer and R. D. DiMarchi, pI-shifted
insulin analogs with extended in vivo time action and favorable receptor selectivity,
Peptides , 28, 935-948 (2007).
[89] W. F. Heath, R. M. Belagaje, G. S. Brooke, R. E. Chance, J. A. Hoffmann, H. B. Long,
S. G. Reams, C. Roundtree, W. N. Shaw, L. J. Slieker, K. L. Sundell and
R. D. DiMarchi, (A-C-B) human proinsulin, a novel insulin agonist and intermediate
in the synthesis of biosynthetic human insulin, J. Biol. Chem ., 267, 419-425 (1992).
[90] P. Kurtzhals, B. Kiehr and A.R. Sørensen, The cobalt(III)-insulin hexamer is a
prolonged-acting insulin prodrug, J. Pharm. Sci ., 84, 1164-1168 (1995).
[91] P. Kurtzhals and U. Ribel, Action profile of cobalt(III)-insulin. A novel principle of
protraction of potential use for basal insulin delivery, Diabetes , 44, 1381-1385
(1995).
[92] T. M. Allen and P. R. Cullis, Drug delivery systems: Entering the mainstream,
Science , 303, 1818-1822 (2004).
[93] S. Huille, N. Bryson, A. Constancis, L. Mohadjer, R. Meyrueix and G. Soula,
Controlled release of insulin from nanoparticles of amphiphilic block copolyamino
acid, J. Control. Rel ., 64, 319-321 (2000).
[94] T. Laugel, O. Crambes, S. Huille, L. Mohadjer, P. Vivet, C. Bloy, M. Rousseau,
R. Meyrueix and G. Soula, In vivo profile of Basulin TM , a new long-acting insulin
formulation with polyamino acid nanoparticles, J. Control. Rel ., 64, 276-278
(2000).
[95] S. Y. Lin, L. T. Ho and H. L. Chiou, Microencapsulation and controlled release of
insulin from polylactic acid microcapsules, Biomat. Med. Dev. Art. Org , 13, 187-201
(1985).
[96] P. Kurtzhals, S. Havelund, I. Jonassen, B. Kiehr, U. D. Larsen, U. Ribel and
J. Markussen, Albumin binding of insulins acylated with fatty acids: characterization
of the ligand-protein interaction and correlation between binding affinity and timing
of the insulin effect in vivo, Biochem. J ., 312 (Pt 3), 725-731 (1995).
[97] P. Kurtzhals, S. Havelund, I. Jonassen, B. Kiehr, U. Ribel and J. Markussen, Albumin
binding and time action of acylated insulins in various species, J. Pharm. Sci ., 85,
304-308 (1996).
[98] P. Kurtzhals, S. Havelund, I. Jonassen and J. Markussen, Effect of fatty acids and
selected drugs on the albumin binding of a long-acting, acylated insulin analogue,
J. Pharm. Sci ., 86, 1365-1368 (1997).